Trial · NCT03826563
Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms
NCT03826563, Not applicable, Completed, Children's Hospital of Philadelphia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms. Trials, record NCT03826563. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03826563
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Melatonin Effects on Sleep and Circadian Rhythm in Youth and Young Adults With At-risk Symptoms
- NCT number
- NCT03826563
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 21 participants, actual
- Lead sponsor
- Children's Hospital of Philadelphia
- Conditions
- Psychosis, Sleep
- Interventions
- oral melatonin tablets (NatureMade brand), Placebo
- First posted
- 2019-02-01
- Last updated
- 2023-05-09
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Actigraph-measured sleep (increased total sleep time) | Change in total sleep time from melatonin randomization day (Day 0) to Day 14 | Actigraph-measured total sleep time will be used to assess actigraph-measured sleep efficacy, Actigraphs from the Actigraph Company will be used to analyze the data using Actilife software. |
| Secondary | Improved self-reported sleep | Change in total PSQI from melatonin randomization day (Day 0) to Day 14 | Pittsburgh Sleep Quality Index (PSQI); range is 0-21, with higher scores indicating poorer sleep |
| Other | Decreased actigraph-measured sleep latency | Change in actigraph-measured sleep onset latency from melatonin randomization day (Day 0) to Day 14 | How long it takes a participant to fall asleep; Actigraphs from the Actigraph Company will be used to analyze the data using Actilife software. Sleep latency is an Actilife software outcome. |
| Other | Increased actigraph-measured sleep efficiency | Change from Randomization day (Day 0) to Day 14. | Amount of time participant spends sleeping divided by the amount of time the patient spends in bed. Actigraphs from the Actigraph Company will be used to analyze the data using Actilife software. Sleep efficiency is an Actilife software outcome. |
| Other | Lower autocorrelation function | Change in actigraph-measured autocorrelation from melatonin randomization day (Day 0) to Day 14 | Ac is the slope of the time correlation line (log-trans- formed); indicative of rhythm fragmentation; lower values represent less fragmented rhythms. Actigraphs from the Actigraph Company will be used to analyze the data using Actilife software. Autocorrelation function is an Actilife software outcome. |
| Other | Increased activity (M10) | Change in actigraph-measured M10 from melatonin randomization day (Day 0) to Day 14 | mean activity level during the most active 10 h of the day; higher values are indicative of a more active lifestyle. M10 is an Actilife software output. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03826563
GET https://conductscience.org/api/trials/v1/NCT03826563/registered